



# UPTAKE OF TREATMENT FOR HCV INFECTION IN PWID IN BELGIUM: THE LINK STUDY

*Bielen R<sup>1,2</sup>, Arain A<sup>1,2</sup>, Busschots D<sup>1,2</sup>, Koc ÖM<sup>1,2</sup>, Nevens F<sup>3</sup>, Trabert C<sup>4</sup>, Werenne J<sup>5</sup>,  
Leonardy N<sup>6</sup>, Mulkay JP<sup>7</sup>, Bourgeois S<sup>8</sup>, Matheï C<sup>9</sup>, Robaey G<sup>1,2,3</sup>*

<sup>1</sup>Hasselt University, <sup>2</sup>Ziekenhuis Oost-Limburg, <sup>3</sup>University Hospitals KULeuven, <sup>4</sup>C.A.P. Fly asbl Liège, <sup>5</sup>Projet LAMA asbl Bruxelles, <sup>6</sup>Maison d'Accueil Socio-Sanitaire (MASS) asbl Bruxelles, <sup>7</sup>Hôpital Saint-Pierre Bruxelles, <sup>8</sup>ZNA Antwerp Belgium, <sup>9</sup>Free Clinic vzw Antwerp

## Disclosures

This project has been made possible thanks to a pharmaceutical grant by MSD<sup>®</sup>, enregistered R-3800 at Hasselt University.

Dr. Rob Bielen has received travel grants from Abbvie<sup>®</sup>, MSD<sup>®</sup> and Gilead<sup>®</sup> to attend scientific congresses.

Prof. dr. Frederik Nevens has received multiple research grants, has received consultancy agreements and has received travel grants from UCB<sup>®</sup>, Ipsen<sup>®</sup>, Roche<sup>®</sup>, Astellas<sup>®</sup>, Ferring<sup>®</sup>, Novartis<sup>®</sup>, Janssen-Cilag<sup>®</sup>, Abbvie<sup>®</sup>, Gilead<sup>®</sup>, CAF<sup>®</sup>, Intercept<sup>®</sup>, Gore<sup>®</sup>, BMS<sup>®</sup>, MSD<sup>®</sup>, Promethera Biosciences<sup>®</sup>, Ono Pharma<sup>®</sup>, Durect<sup>®</sup>.

Dr. Stefan Bourgeois has acted as a consultant/advisor and received speakers fees from AbbVie, MSD, BMS, Gilead and J&J.

Prof. dr. Geert Robaey has received research grants from Merck Sharp & Dohme<sup>®</sup>, AbbVie<sup>®</sup>, Janssen Pharmaceuticals<sup>®</sup>, and has acted as a consultant/advisor and for Gilead Sciences<sup>®</sup>, Abbvie<sup>®</sup>, Merck Sharp & Dohme<sup>®</sup>, and Bristol Myers-Squibb<sup>®</sup>.

The other authors have nothing to disclose.



## Aim

To study the uptake for HCV treatment in PWID in Belgium


To study factors influencing treatment uptake



## Methods

	<b>ETHOS</b> (2013 – Alavi et al.)	<b>LINK</b>
Participants (n)	387	256
Methodology	Prospective observational	Prospective observational
Follow-up	Each six months	yearly
Network	9 clinics (NSW, Australia)	5 clinics (Belgium)
Inclusion period	February 2009 – December 2012	June 2012 – November 2016
Follow-up	2 years	2 years
Inclusion criteria	≥ 18 years old Chronic HCV infection IDU history No HCV treatment	≥ 18 years old Chronic HCV infection IDU history No HCV treatment

## Results



Variable	P- value	OR	95% CI
OST center	.011	12.003	1.764 ; 81.680
Male gender	.019	4.739	1.294 ; 17.355
Netto income > €700/month	.017	5.470	1.363 ; 21.949
Treatment willingness	.027	13.769	1.341 ; 141.341
Treatment assessment			
Liver biopsy	<.001	11.211	4.555 ; 27.596
Fibroscan	.005	3.939	1.511 ; 10.267
Referral to specialist	.053	2.961	.988 ; 8.876

## Conclusions/limitations

### Major limitations

1. Long inclusion period during an era of HCV treatment revolution
2. Reimbursement restrictions Belgium

### Conclusion

1. Additional data collection in DAA era
2. Survival analysis

## Acknowledgements

- Thanks to all the people who inject drugs who have generously participated in this research
- Thank you to all the nurses/social workers to continuously provide the efforts to reach out to the participants, more specifically thanks to Griet Maertens, Barbara Kulakowski, Sarah Vanderwaeren, Isabelle Demoulin, Amandine Masuy, Eefje Dercon, and Virginie Renwart
- This project is part of a PhD project within the Limburg Clinical Research Program of Hasselt University, Ziekenhuis Oost-Limburg, Genk and Jessa Hospital Hasselt.



Projet Lama ASBL

